MA32751B1 - Antagoniste sélectif du récepteur opioïde kappa - Google Patents
Antagoniste sélectif du récepteur opioïde kappaInfo
- Publication number
- MA32751B1 MA32751B1 MA33041A MA33041A MA32751B1 MA 32751 B1 MA32751 B1 MA 32751B1 MA 33041 A MA33041 A MA 33041A MA 33041 A MA33041 A MA 33041A MA 32751 B1 MA32751 B1 MA 32751B1
- Authority
- MA
- Morocco
- Prior art keywords
- opioid receptor
- selective antagonist
- receptor kappa
- kappa
- selective
- Prior art date
Links
- 102000003840 Opioid Receptors Human genes 0.000 title 1
- 108090000137 Opioid Receptors Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 239000002618 kappa opiate receptor antagonist Substances 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08380012 | 2008-01-22 | ||
| US3912108P | 2008-03-25 | 2008-03-25 | |
| PCT/US2009/030811 WO2009094260A1 (en) | 2008-01-22 | 2009-01-13 | Kappa selective opioid receptor antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA32751B1 true MA32751B1 (fr) | 2011-11-01 |
Family
ID=40876972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA33041A MA32751B1 (fr) | 2008-01-22 | 2010-07-19 | Antagoniste sélectif du récepteur opioïde kappa |
Country Status (32)
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA017484B1 (ru) * | 2008-01-22 | 2012-12-28 | Эли Лилли Энд Компани | Селективный антагонист опиоидных рецепторов каппа |
| NZ587215A (en) * | 2008-01-22 | 2012-08-31 | Takeda Pharmaceutical | Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them |
| WO2013040321A1 (en) * | 2011-09-15 | 2013-03-21 | University Of Kansas | Kappa opioid receptor effectors and uses thereof |
| WO2013042054A1 (en) | 2011-09-19 | 2013-03-28 | Carmel - Haifa University Economic Corporation Ltd. | Buprenorphine for the treatment of acute suicidality |
| CA2858752C (en) | 2011-12-09 | 2019-12-31 | Research Triangle Institute | 1-substituted 4-arylpiperazines as kappa opioid receptor antagonists |
| WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| US9283196B1 (en) | 2013-01-30 | 2016-03-15 | MediSynergics, LLC | Cycloalkyl-diamines for CNS disorders |
| WO2014190270A1 (en) * | 2013-05-24 | 2014-11-27 | Alkermes Pharma Ireland Limited | Morphan and morphinan analogues, and methods of use |
| US10316021B2 (en) * | 2016-11-28 | 2019-06-11 | Pfizer Inc. | Heteroarylphenoxy benzamide kappa opioid ligands |
| JP7132237B2 (ja) | 2017-03-17 | 2022-09-06 | ザ スクリプス リサーチ インスティテュート | κオピオイド受容体アンタゴニストならびにそれに関連する産物および方法 |
| JP6480616B1 (ja) | 2018-02-08 | 2019-03-13 | 有限会社 ディオン光学技研 | 照準スコープ |
| US11266627B1 (en) | 2021-05-04 | 2022-03-08 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| CN114195693A (zh) * | 2020-09-17 | 2022-03-18 | 广东东阳光药业有限公司 | 一种酰胺化合物的晶型及其制备方法 |
| CN114591211B (zh) * | 2020-12-04 | 2025-10-21 | 广东东阳光药业股份有限公司 | 一种酰胺化合物的共晶及其制备方法 |
| US12161622B2 (en) | 2021-05-04 | 2024-12-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| KR20240004857A (ko) | 2021-05-04 | 2024-01-11 | 얀센 파마슈티칼즈, 인코포레이티드 | 우울증 치료를 위한 조성물 및 방법 |
| CN118843459A (zh) * | 2022-01-10 | 2024-10-25 | 杨森制药公司 | 用于治疗抑郁症的组合物和方法 |
| MX2024008618A (es) * | 2022-01-10 | 2024-09-25 | Janssen Pharmaceuticals Inc | Composiciones y métodos para el tratamiento de la depresión. |
| TW202400135A (zh) * | 2022-03-07 | 2024-01-01 | 美商健生醫藥公司 | 包含阿替卡普蘭之組成物 |
| WO2023170550A1 (en) | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | Polymorph forms of aticaprant for use in treating major depressive disorder |
| CN119156210A (zh) * | 2022-03-07 | 2024-12-17 | 杨森制药公司 | 纯形式的结晶阿替卡普兰 |
| JP7176142B1 (ja) | 2022-03-09 | 2022-11-21 | 直迪 清瀬 | 各アルコール飲用者において飲用し得るアルコール飲料の種類に対応する飲用量の上限値に関する情報を提供するシステム |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5457208A (en) | 1993-06-21 | 1995-10-10 | Regents Of The University Of Minnesota | Kappa opioid receptor antagonists |
| CA2372040C (en) * | 1999-05-12 | 2008-12-02 | Francois Jenck | Imidazodiazepine derivative |
| WO2002029418A1 (en) * | 2000-10-05 | 2002-04-11 | Hanns Mohler | Selective anxiolytic therapeutic agents |
| US6528518B2 (en) | 2000-12-21 | 2003-03-04 | The Mclean Hospital Corporation | Treatment of depression with kappa receptor antagonists |
| US6974824B2 (en) | 2001-01-08 | 2005-12-13 | Research Triangle Institute | Kappa opioid receptor ligands |
| BR0308918A (pt) * | 2002-03-28 | 2005-01-04 | Wisys Technology Found Inc | Agentes ansiolìticos com efeitos sedativos e atáxicos reduzidos |
| MY140236A (en) | 2002-09-19 | 2009-12-31 | Lilly Co Eli | Diarylether compounds useful as opioid receptor antagonists |
| BRPI0407616A (pt) | 2003-03-07 | 2006-02-14 | Lilly Co Eli | composto, composição farmacêutica, método para bloquear uma combinação de receptor de mu, capa, delta (heterodìmero) deste em mamìferos, método para tratar ou prevenir obesidade e doenças relacionadas, uso de um composto, e método de suprimir o apetite em um paciente em necessidade deste" |
| ATE406360T1 (de) | 2003-03-07 | 2008-09-15 | Lilly Co Eli | Antagonisten der opioidrezeptoren |
| US7196100B2 (en) | 2003-12-12 | 2007-03-27 | Eli Lilly And Company | Opioid receptor antagonists |
| AU2004312312A1 (en) | 2003-12-22 | 2005-07-21 | Eli Lilly And Company | Opioid receptor antagonists |
| WO2005089745A1 (en) | 2004-03-12 | 2005-09-29 | The Mclean Hospital Corporation | Salvinorin derivatives and uses thereof |
| CA2558568A1 (en) | 2004-03-12 | 2005-09-29 | Eli Lilly And Company | Opioid receptor antagonists |
| JP2007528898A (ja) | 2004-03-12 | 2007-10-18 | イーライ リリー アンド カンパニー | オピオイド受容体拮抗物質 |
| WO2005092836A1 (en) | 2004-03-15 | 2005-10-06 | Eli Lilly And Company | Opioid receptor antagonists |
| DE602005012380D1 (de) | 2004-03-15 | 2009-03-05 | Lilly Co Eli | 4-(5-(aminomethyl)-indol-1-ylmethyl)benzamidderivate und verwandte verbindungen als opioidrezeptorantagonisten zur behandlung von fettleibigkeit |
| WO2007067714A2 (en) | 2005-12-08 | 2007-06-14 | The Mclean Hospital Corporation | Treatment of sequelae of psychiatric disorders |
| DE502007002185D1 (de) | 2006-04-04 | 2010-01-14 | Emodys Gmbh | Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen |
| JP2010500372A (ja) | 2006-08-09 | 2010-01-07 | スミスクライン ビーチャム コーポレーション | オピオイド受容体に対するアンタゴニストまたはインバースアゴニストとしての新規化合物 |
| CN101522614B (zh) | 2006-08-09 | 2014-06-25 | 史密丝克莱恩比彻姆公司 | 作为阿片样物质受体的拮抗剂或反向激动剂的化合物 |
| CA2662766C (en) | 2006-09-08 | 2011-08-09 | Pfizer Products Inc. | Diaryl ether derivatives and uses thereof |
| EA017484B1 (ru) * | 2008-01-22 | 2012-12-28 | Эли Лилли Энд Компани | Селективный антагонист опиоидных рецепторов каппа |
-
2009
- 2009-01-13 EA EA201070877A patent/EA017484B1/ru not_active IP Right Cessation
- 2009-01-13 WO PCT/US2009/030811 patent/WO2009094260A1/en not_active Ceased
- 2009-01-13 EP EP09703808A patent/EP2252581B1/en active Active
- 2009-01-13 MX MX2010007849A patent/MX2010007849A/es active IP Right Grant
- 2009-01-13 PL PL09703808T patent/PL2252581T3/pl unknown
- 2009-01-13 HR HRP20120558AT patent/HRP20120558T1/hr unknown
- 2009-01-13 AU AU2009206653A patent/AU2009206653B2/en active Active
- 2009-01-13 JP JP2010543182A patent/JP5345637B2/ja active Active
- 2009-01-13 DK DK09703808.7T patent/DK2252581T3/da active
- 2009-01-13 CN CN2009801026504A patent/CN101925576B/zh active Active
- 2009-01-13 SI SI200930326T patent/SI2252581T1/sl unknown
- 2009-01-13 US US12/352,869 patent/US7709522B2/en active Active
- 2009-01-13 CA CA2713025A patent/CA2713025C/en active Active
- 2009-01-13 PE PE2009000036A patent/PE20091317A1/es active IP Right Grant
- 2009-01-13 KR KR1020107016401A patent/KR101172170B1/ko active Active
- 2009-01-13 PT PT09703808T patent/PT2252581E/pt unknown
- 2009-01-13 JO JO200915A patent/JO2797B1/en active
- 2009-01-13 NZ NZ586225A patent/NZ586225A/en unknown
- 2009-01-13 MY MYPI2010003437A patent/MY163014A/en unknown
- 2009-01-13 BR BRPI0907382A patent/BRPI0907382B8/pt active IP Right Grant
- 2009-01-13 TW TW098101083A patent/TWI422369B/zh active
- 2009-01-13 AR ARP090100098A patent/AR070158A1/es not_active Application Discontinuation
- 2009-01-13 UA UAA201008931A patent/UA100715C2/ru unknown
- 2009-01-13 ES ES09703808T patent/ES2388708T3/es active Active
-
2010
- 2010-04-09 US US12/757,451 patent/US8173695B2/en active Active
- 2010-05-27 IL IL206038A patent/IL206038A/en active IP Right Grant
- 2010-06-01 ZA ZA2010/03908A patent/ZA201003908B/en unknown
- 2010-06-30 TN TN2010000306A patent/TN2010000306A1/fr unknown
- 2010-07-19 MA MA33041A patent/MA32751B1/fr unknown
- 2010-07-20 DO DO2010000222A patent/DOP2010000222A/es unknown
- 2010-07-22 EC EC2010010365A patent/ECSP10010365A/es unknown
- 2010-08-12 CO CO10099271A patent/CO6290644A2/es active IP Right Grant
-
2012
- 2012-08-24 CY CY20121100765T patent/CY1113071T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2324029A4 (en) | HETEROCYCLIC HEMMER OF HISTAMINE RECEPTORS FOR DISEASE TREATMENT | |
| UA112055C2 (uk) | Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну | |
| EA200900152A1 (ru) | Ингибиторы пирролотриазинкиназы | |
| MA32898B1 (fr) | Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone | |
| HRP20090235A2 (hr) | Karbonilirani (aza) cikloheksani kao ligandi dopaminskog receptora d<sub>3</sub> | |
| MA31084B1 (fr) | Derives de piperidine agonistes de gpcr | |
| MA35285B1 (fr) | Indazoles | |
| ATE524450T1 (de) | 5-phenyl-isoxazol-3-carboxamid-derivate als trpv1-modulatoren | |
| MA34361B1 (fr) | Dérivés de tétrahydro-pyrido-pyrimidine | |
| EP2282795A4 (en) | TREATMENT OF RESPIRATORY DISEASES | |
| EP2320904A4 (en) | AMINOPYRIMIDINE HEMMER OF HISTAMINE RECEPTORS FOR DISEASE TREATMENT | |
| BR112014003237A2 (pt) | compostos de indazol, composições e métodos de uso | |
| MA33053B1 (fr) | Inhibiteurs de la poly(adp-ribose) polymerase (parp) | |
| MA33428B1 (fr) | Agonistes du gpr119 | |
| MA31593B1 (fr) | Derives de 2-aza-bicyclo[3.3.0]octane | |
| MA31158B1 (fr) | Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes | |
| BRPI0714315B8 (pt) | arilamidas substituídas com tetrazol, seu uso e composição farmacêutica que as compreende | |
| MA31910B1 (fr) | Antagonistes des recepteurs non steroidiens des mineralocorticoides derives de la 6h-dibenzo[b,e]oxepine | |
| TW200800958A (en) | N-substituted-azacyclylamines as histamine-3 antagonists | |
| DE602007006961D1 (de) | Cgrp-rezeptorantagonisten | |
| BRPI0907382B8 (pt) | antagonista de receptor de opioide seletivo capa, seu uso e composição farmacêutica que o compreende | |
| DK2081572T3 (da) | Benzimidazol-cannabinoid-agonister med en substitueret heterocyklisk gruppe | |
| DE602007006019D1 (de) | Für die behandlung von durch den gpr38-rezeptor vermittelten krankheiten geeignete piperazinylderivate | |
| ATE534632T1 (de) | Thiazole, imidazole und pyrazole als proteinkinasehemmer | |
| MA30703B1 (fr) | Dérivés de 5,6-bisaryl-2-pyridine-carboxamide, leur préparation et leur application en thérapeutique comme antagonistes des recepteurs a l'urotensine ii. |